These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22147537)

  • 1. Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy.
    St Clair EW
    Arthritis Rheum; 2012 Mar; 64(3):604-8. PubMed ID: 22147537
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.
    Sneller MC; Hu Z; Langford CA
    Arthritis Rheum; 2012 Mar; 64(3):835-42. PubMed ID: 22147444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
    De Vita S; Quartuccio L; Isola M; Mazzaro C; Scaini P; Lenzi M; Campanini M; Naclerio C; Tavoni A; Pietrogrande M; Ferri C; Mascia MT; Masolini P; Zabotti A; Maset M; Roccatello D; Zignego AL; Pioltelli P; Gabrielli A; Filippini D; Perrella O; Migliaresi S; Galli M; Bombardieri S; Monti G
    Arthritis Rheum; 2012 Mar; 64(3):843-53. PubMed ID: 22147661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Kidney involvement in mixed cryoglobulinemia: which treatment?].
    Cacoub P
    Presse Med; 2012 Mar; 41(3 Pt 1):254-9. PubMed ID: 22192935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.
    Cacoub P; Terrier B; Saadoun D
    Presse Med; 2013 Apr; 42(4 Pt 2):523-7. PubMed ID: 23453499
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Delluc A; Piette JC; Cacoub P
    Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Successful rituximab therapy of HCV-cryoglobulinemic vasculitis with severe ulcerative and necrotic lesions of the skin].
    Ignatova TM; Chernova OA; Gaĭdasheva EV
    Klin Med (Mosk); 2012; 90(5):64-6. PubMed ID: 22993956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term remission with rituximab in a patient with severe hepatitis C virus-induced mixed cryoglobulinemia.
    Fortea-Ormaechea JI; Lozano-Maya M; Adán-Merino L; Barrio-Antoranz J; Martín-Chavarri S; Corchete-Prats E; Martínez-Acebes E; Aldeguer-Martínez M
    Rev Esp Enferm Dig; 2013 Sep; 105(8):490-3. PubMed ID: 24274448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update in rheumatology: evidence published in 2012.
    Deodhar A
    Ann Intern Med; 2013 Jun; 158(12):903-6. PubMed ID: 23580081
    [No Abstract]   [Full Text] [Related]  

  • 10. The dilemma of treating hepatitis C virus-associated cryoglobulinemia.
    Roccatello D; Fenoglio R; Sciascia S
    Curr Opin Rheumatol; 2019 Sep; 31(5):499-504. PubMed ID: 31090590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab.
    Cai FZ; Ahern M; Smith M
    J Rheumatol; 2006 Jun; 33(6):1197-8. PubMed ID: 16755669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis.
    Cohen C; Mekinian A; Saidenberg-Kermanac'h N; Stirnemann J; Fenaux P; Gherardi R; Fain O
    Ann Rheum Dis; 2012 Apr; 71(4):628-9. PubMed ID: 22121135
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
    Ignatova TM; Mukhin NA
    Ter Arkh; 2012; 84(11):81-8. PubMed ID: 23252255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report.
    Massari M; Catania A; Magnani G
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S134-5. PubMed ID: 17936216
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients.
    Terrier B; Saadoun D; Sène D; Sellam J; Pérard L; Coppéré B; Karras A; Blanc F; Buchler M; Plaisier E; Ghillani P; Rosenzwajg M; Cacoub P
    Arthritis Rheum; 2009 Aug; 60(8):2531-40. PubMed ID: 19644879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful treatment of severe HCV-cryoglobulinemic vasculitis with the use of CD20 monoclonalantibodies and antiviral agents].
    Ignatova TM; Chernova OA; Burnevich EZ; Milovanova SIu
    Klin Med (Mosk); 2014; 92(8):62-4. PubMed ID: 25790700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis.
    Lamprecht P; Lerin-Lozano C; Merz H; Dennin RH; Gause A; Voswinkel J; Peters SO; Gutzeit O; Arlt AC; Solbach W; Gross WL
    Ann Rheum Dis; 2003 Dec; 62(12):1230-3. PubMed ID: 14644867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential mixed cryoglobulinemia type III with leukocytoclastic vasculitis: remission by rituximab.
    Baerlecken NT; Schmidt RE
    Clin Rheumatol; 2013 Mar; 32 Suppl 1():S19-20. PubMed ID: 20213127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Twenty-seven years' activities of the French vasculitis study group (FVSG)].
    Guillevin L
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S263-5. PubMed ID: 18029060
    [No Abstract]   [Full Text] [Related]  

  • 20. New insights in cryoglobulinemic vasculitis.
    Silva F; Pinto C; Barbosa A; Borges T; Dias C; Almeida J
    J Autoimmun; 2019 Dec; 105():102313. PubMed ID: 31383568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.